Endothelial dysfunction - Update and clinical implications;Endotheliale dysfunktion - Eine bestandsaufnahme und ansaetze zur therapie

Herz

Volumn 24, Issue 1, 1999, Pages 62-71

  Simon, Bernd C ^a   Noll, Bernd ^a   Maisch, Bernhard ^a  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

Atherosclerosis; Endothelium; Nitric oxide

Indexed keywords

ARGININE; INTERCELLULAR ADHESION MOLECULE 1; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; SELECTIN; VASCULAR CELL ADHESION MOLECULE 1;

ATHEROSCLEROTIC PLAQUE; BIOSENSOR; EARLY DIAGNOSIS; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; LEUKOCYTE ADHERENCE; PATHOPHYSIOLOGY; PROTEIN INTERACTION; REVIEW; RISK FACTOR; THROMBOCYTE ACTIVATION; VASCULAR ENDOTHELIUM;

EID: 0032984957     PISSN: 03409937     EISSN: None     Source Type: Journal    
DOI: 10.1007/bf03043820     Document Type: Review

References (80)

1. Andersen TJ, Meredith I, Yeung AC, et ai. The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependcr.t coronary vasomotion. K Engl .1 .Vied 1995;332:488-93.
2. Beckman JS, Ye ZY, Anderson PG, cf al. Extensive nitration of protein tyrosines in human atSierosclerosis detected by irnmunohistocherrustry. Hoppe-Seylers Z Physiol Chem 1994:375:81-8.
3. Bevilacqua VIP. Hndothelial-lcucocyte adhesion molecules. Ann Rev Immunol 1993:11:767-804.
4. Boulanger CM, Tanner FC, Bea ML, et al. Oxidized low density iipoprotcins induce mRNA expression and release ofendolhelin from human and porcine endotheiium. Circ Res 1992;70:ii91-7.
5. Bredt DS, Hwang PH, Glatt C, et al. Cloned and expressed nitric oxide svnthase structurally resembles cytochrome P-450 reductase. Nature 1991:351:714-8.
6. Buttery LD, Springall DR. Chester AH, et al. Inducible nitric oxide synthase is present within human atherosclerotic iesions and promotes the formation and activity of peroxynitrile. Lab Invest 1996:75:77-85.
7. Campbell LA, O'Brien ER, Cappuccio AL, et al. Detection of Chlamydia pneurnoniae TYVAR in human coronary atherectomy tissues. J Infect Dis 1995:172:585-8.
8. Cayatte AJ, Palacino JJ, Horten K, et al. Chronic inhibition of nitric oxide production accelerates neointima formation and impairs endothclial function in hypercholesterolemic rabbits. Arlerioscler Thromb 1994:14:753-9.
9. Celermajer DS, Sorensen KE, Gooch VM, et al. Noninvasive de tection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet 1992:340:1111-5.
10. Cibulski Ml, Gimbrone MA Jr. Endothelial expression of mononuclear leukocyte adhesion rnolecuie during atherogenesis. Science 1991:251:788-91.
11. Cohen RA, Zitnay KM. Haudenschild CC, et al. Loss of selective endoihelial cell vasoactive functions caused by hypercholesterolernia in pig coronary arteries. Circ Res 1988;63:903-10.
12. Collins P, Rosano GMC, Sarrel PM, et al. 17β-estradioi attenuates acetylcholine-induced coronary artery constriction in women but not in men with coronary heart disease. Circulation 1995:92:24-30.
13. CookeJP, Singer AH, Tsao P, et al. Antiatherogcnic effects of Larginine in the hypercholestrolernic rabbit. J Clin Invest 1992;90: 1168-72.
14. Cox DA, Vita JA, Treasure CB, et al. Atherosclerosis impairs flow-mediated dilation of coronary arteries in humans. Circulation 1989:80:458-65.
15. Creager MA, Cooke .IP, Mendelsohn ME, et al. Impaired vasodilalion of forearm resistance vessels in hypercholesterolemic humans. J Clin Invest 1990:86:228-34.
16. Drexler H, Zeiher AM, Mainzer K, et al. Correction of endotheliai dysfunction in coronary microcircuiation of hypercholesterolemic patients rry L-arginine. LanccT 1991:338:1546-50.
17. Drexler H, Zeiher AM. Wollschläger H. ei al. Flow-dependent coronary artery dilatation in humans. Circulation 1989;80:466-74.
18. Drexler H. Zeiher AM Köster W, et al. Er.dothelial dysfunction in the coronary circulation in hypcrcholesterolemia: effect of high HDL-cholcstcrol. Circulation 1992:86:Suppl 1:467.
19. tgashira K. Kai HY, et al. Reduction in serum cholesterol with pravastatin improves endothelium-dcpendent coronary vasornolion in p. j Infect Dis 1995:l72:585-8.
20. Frciman PC, Mitchell GC. Helstad DD. et al. Atherosclerosis impairs endothelium-dependeni vascular relaxation to acetylcholine and thromhin in primates. Circ Res 1986:58:783-9.
21. Furchgoft RF. Zawadzki JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 1980:228:373-6.
22. Garg L1C, Hassid A. Nitric oxide-generating vasodilators and 8bromo-cyclic guanosine monophospliate inhibit mhogenesis and proliferation of cultured rat vascular smooth muscle cells, j Clin Invest 1989:83:1774-7.
23. Gruetter CA, Gruetter DY, Lyon JE. et al. Relationship between cyclic guanosine 3′:5′-monophosphate formation and relaxation of coronary arterial smooth muscle by glycery! triniuate. niiroprusside, nitrite and nitric oxide: effects of methyleene blue and methemoglobin. J Pharmacol Exp Ther 1981:219:181-6.
24. Gryglewski RJ, Palmer RMJ, Moncada S. Superoxide anion is involved in the breakdown of edndothelium-derivecl vascular relaxing factor. Nature 1986:320:454-6.
25. Heitzer T, Just H. Münzel T. Antioxidant vitamin C improves endothelial dysfunction in chronic smokers. Circulation \ 996:94:6-9.
26. HirataK, MikiN, Kuroda Y, etal. Low concentration of oxidized low density lipoprolein and lysophosphatidylcholine upregulate constitutive nitric oxide synthase mRNA expression in bovine aortic endothelial cells. Circ Res 1995:76:958-62.
27. Huang PL, Huang Z, Mi.shimo H, et al. Hypertension in mice lacking the gene for endothelial nitric oxide synthase. Nature 1995:377:2392.
28. Ignarro LJ. Buga CM, Wood KS, et al. Endothclium-derived relaxing factor produced and released from artery and vein is nitric oxide. Proc Natl Acad Sei USA 1987:84:9265-9.
29. Kubes P, Suzuki M, Granger DN. Nitric oxide: an endogenous modulator of leukocyte adhesion. Proc Natl Acad Sei USA 1991;88:4651-5,
30. Lamas S, Marsden PA. Li GK, el ai. Endothelial nitric oxide synthase: molecular cloning and characterization of a distinct constitutive en/yme isoform. Proc Natl Acad Sei 1992:89:6348-52.
31. Lerman A, Holmes DR Jr, Bell MR, et al. Endothelin in coronary endothelial dysfunction and early atherosclerosis in humans. Circulation 1995:92:2426-31.
32. Lerman A, Edwards BS. Hallett JW, et al. Circulating and tissue endothelin immunoreactivity in advanced atherosclerosis. N Engl J Vied 1991 ;325:997-l 001.
33. Lerman A.I, Burnett JC jr. Intact and altered endotheiium in regulation oi'vasomotion. Circulation 1992:86:1112-9.
34. Leung WH. Pak LC, Wong CK. Beneficial effects of cholesterollowering therapy on coronary cndothelium-depenclent relaxation in hypercholcsteroiemic patients. Lancet 1993;341:1496-500.
35. Levine GN. Frei B, Koulouris SN, el al. Ascorbic acid reverses endothelial vasomoior dysfunction in patients with coronary artery disease. Circu.ation 1996:93:1107-13.
36. Liao JK. Inhibition of Gi proteins by low density lipoprotein attenuates bradykinin-stimulated release of endothelial-dcrivcd nitric oxide. J Biol Chem 1994:269:19528-33.
37. Liao JK, Shin WS, Lee WY. et al. Oxidized low density lipoprotein decreases the expression of endothelial nitric oxide synthase. J Biol Chem 1994:270:319-24.
38. Libby P. Inflammatory and immune mechanisms in alherogenesis. In: Leaf A, Weber P, eds. Atherosclerosis reviews. New York: Raven Press. 1990:79-89.
39. Libby P. Clinton SK. The role of macrophages in alherogenesis. Curr Opin Lipidoi 1993:4:355-63.
40. Luseher TF. Endothelium in the control of vascular tone and growth: role of local mediators and mechanical forces. Blood Pressure 1994;::Suppl:IS-22.
41. Lyons CR, Orloff GJ, Cunningham JVI. Molecular cloning and functional expression of an induciblc nitric oxide synthase from a murine macrophage cell line. J Biol Chem 1992:267:6370-4.
42. Martin-Mzaro F. Houssaini HS, Lestavel-Delattre S, et al. Modified low density lipoproteins activate human macrophages to secrete irnmunorcactive endotheiin. FEES Lett 1991:293:127-30.
43. McLenachan JM, Williams JK. Fish RD. et al et al. Loss of nowmediated endolhelium-dependent dilation occurs early in the development of atherosclerosis. Circulation 1991:84:1273-8.
44. Minor RL, Myers PR, Ouerra R, et al. Diet-induced atherosclerosis increases the release of nitrogen oxides from rabbii aorta. J Clin Invest 1990:86:2109-16.
45. Moncada S, Palmer RM, Higgs EA. Nitric oxide physiology, pathophysiology and pharmacology. Pharmacol Rev I991;43: 109-42.
46. Moroi VI. Zhang L, Yasuda T, et al. Interaction of genetic deficiency of endotheiial nitric oxide, gender and pregnancy in vascular reponse to injury in mice. J Clin invest 1998:101:1225-32.
47. Murad F. Regualtion of cytosolic guanylyl cyclase by nitric oxide: the \O-cyclic GMP signal transouction system. Adv Pharmacol 1994:26:19-33.
48. MyersRP, Minor RL.Ir, Fuerra R Jr. et al. Vasorelaxant properties of the endothelium-dcrived relaxant factor more closely resemble S-nitrosocysteine than nitric oxide. Nature 1990:345:161-3.
49. Nishida K, Flarrison DO, N'avas JP, et al. Molecular cloning and characterisation of the constitutive bovine aortic endothlial cell nitric oxide synthase. J Clin Invest 1992:90:2092-6.
50. Niu XF. Smith CW, Kubes P. Intracellular oxidativc stress induced by nitric oxide synthesis inhibition increases endotheiial cell adhesion to ncutrophils. Circ Res 1994:74:1133-40.
51. Ohara Y, Peterson TE, Sayegh FIS. et a!. Dietary correction of hypercholesterolemia in the rabbit normalizes endotheiial superoxide anion production. Circulation 1995:92:898-903.
52. Ohara Y, Peterson TE, Harrison DG. Flypercholesterolemia increases endotheiial Superoxide anion production. J Clin Invest 1993:91:2546-51.
53. Palmer RMJ, Ferridge AG, Moncada S. Xitric oxide release accounts for the biological activity of endothe'ium-dcrived relaxing factor. Nature 1987:327:524-6.'
54. Panza JA, Quyyumi AA, Callahan TS, et al. Effect of antihypertcnsive treatment on endothelium-dependem vascular relaxation in patients with essential hypertension. J Am Coll Cardiol 1993;21:1145-51.
55. Pearson JD. Baillers Clin Haernat 1994;7:441-52.
56. Pohl U, DezsiL, Simon B.et al. Selective inhibition of endothelium-dependent dilation in resistance-sized vessels in vivo. Am J Physiol 1987;253:H234-9.
57. Radomski MW, Pamier RMJ, Moncada S. Comparative pharmacology of endothelium-derived relaxing factor, nitric oxide and proslacyclin in platelets. Br J Pharmacol 1987:92:181-7.
58. Radl R, Beckman JW, Bush KM. et al. Peroxynitrite induced membrane lipid peroxidation: the cyiotoxic potential of Superoxide and nitric oxide. Arch Biochem Biophys 1991:288:481-7.
59. Reddy KG, Nair RN, Sheehan HM, et al. Evidence that selective endotheiial dysfunction may occur in the absence of angiographie or ultrasound atherosclerosis in patients with risk factors for atherosclerosis. J Am Coll Cardiol 1994:23:8333.
60. Rubani GM, Romero JC. Vanhoutte PM. Flow-induced release of endothelium-derived relaxing factor. Am J Physiol 1986:250: H1145-9.
61. Saikku P. Leinenen M. Mattila K. et al. Serological evidence of an association of a novel Chlamydia. TWAR. vvith chronic coronary heart diseuse and acute myocardial infarction. Lancet 1988:2:983-6.
62. Schreck R. Albermann K, Baeuerle PA. Nuclear factor-κB: an oxidative stress-responsive transcription factor of eukaryotic cells. Free Radicals Res Commun 1992:17:221-37.
63. Shepherd j, Cobbc SM, Ford 1. et ai. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995:333:1301-7.
64. Simon BC, Cunningham LD, Cohen RA. Oxidized low density iipoproteins cause contraction and inhibit endothelium-dependent relaxation in the pig coronary artery. J Clin Invest 1990:86:75-9.
65. Simon BC, Haudcnschild CC. Cohen RA. Preservation of endothelium-dependent relaxation in atherosclerotic rabbit aorta by probucol. J Cardiovasc Pharmacoi 1993:21:893-901.
66. Stcinbcrg D. Oxidative modification of LDL and atherogenesis. Circulation 1997:95:1062-71.
67. Treasure CB, Klein JL, Weintraub WS. Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. N Engl J ed 1995:332:481-7.
68. Tsao P, McEvoy LM. Drexler H, et al. Enhanced ednothclial adhesiveness in hypercholesterolemia is attenuated by L-arginine. Circulation 1994;89:2176-82.
69. Vita JA, Treasure CB. Nabel EG, et al. Coronary vasomotor response to acetylcholine relates to risk facotrs for coronary artery disease. Circulation 1990:81:491-7.
70. 7u. Vita J A, Treasure CB, GanzP, etal. Control of shear stress in the epicardial coronary arteries of humans: impairment by atherosclerosis. J Am Coll Cardiol 1989:14:1193-9.
71. Von der Leyen HE, Gibbons GH, Morishita R, el al. Gene therapy inhibiting neointimal vascular Sesion: in vivo transfer of endothelial cell nitric oxide synthase geae. Proc Natl Acad Sei LISA 1995:92:1137-41.
72. Wait GF, Lewi B, Brunt JN. Effects of coronary artery disease of lipid-lo\vering diet, or diet plus cholestyramine, in the St. Thomas' Atherosclerosis Regression Study (STARS). Lancet 1992:339:563-9.
73. Weissberg PL, Witchell C. Davenport AP. et al. The ednothelin peptides ET-1, ET-2. ET-3. and sarafotoxin S6b are co-rnitogenic with platelet-derived growth factor for vascular smooth muscle cells. Atherosclerosis 1990:85:257-62.
74. Werner-Felmayer G, Werner ER. Fachs D. Tetrahydrobiopterin-deper.dent formation of nitrite and nitrate in murir.c fibrobiasts. J Exp Meci 1990:172:1599-607.
75. Werns SW. Walton JA. Hsia KH. ei al. Evidence of endothelia! dysfunction in angiographicully normal coronary arteries of patients with coronary artery disease. Circulation 1989:79:287-91.
76. Yeung AC. Vekshtein VL. Krantz DS. et al. The effect of atherosclerosis on the \asomotor response of coronary arteries to mental stress. N Engl J Mcd 1991:325:1551-6.
77. Zeiher AM. Drexier H. Wollschläger H. et ai. Coronary vasomolion in response to sympathetic stimulation in humans: importance of the functional integrity of the endothelium. .1 Am Coll Cardioi 1989:14:1181-90.
78. Zeiher AM. Goebel H, Schachinger V. et al. Tissue enclothelin-i imrnunoreactivily in the active coronary atherosclerotic plaque: a clue to the mechanism of increased vasorcactivity of the culprit lesion in unstable angina. Circulation 1995:91:941-7.
79. Zhdo XQ, Brown BG. Hillger L. Effects of intensive lipid lowering therapy on on the coronary arteries of asymptomatic subjects with elevated apolipoproiein B. Circulation 1993:88:2744-53.
80. 4S-Trial: Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastalin Survival Study (4S). Lancet 1994:344:1383-9.